Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04101968 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The GBA Multimodal Study in Parkinson's Disease

StatusCompleted
PhaseNot specified
Started2019-05-01
View on ClinicalTrials.gov ↗
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Amendment history 3 changes detected by DataLookout

2026-09-03
Trial completed
2026-09-03
Final enrollment: 30 participants (planned 25)
2026-09-03
Primary completion 2026-06-30, at least 182 days after the final estimate of 2025-12-30
Trial Details
NCT Number NCT04101968
Lead Sponsor Pacific Parkinson's Research Centre
Collaborators: University of British Columbia, University of Washington, Oregon Health and Science University, Simon Fraser University, Michael J. Fox Foundation for Parkinson's Research, Silverstein Foundation, Weston Brain Institute
Conditions Parkinson Disease, GBA Gene Mutation, Gaucher Disease
Enrollment 30 participants
Start Date 2019-05-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-02